home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2837.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
42 lines
Document 2837
DOCN M94A2837
TI Treatment of HIV infected adult patients with high-dose intravenous
immunoglobulin. A randomized trial.
DT 9412
AU Kiehl M; Heese C; Stoll R; Domschke W; Department of Internal Medicine
A, University of Munster,; Germany.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):213 (abstract no. PB0282). Unique
Identifier : AIDSLINE ICA10/94369738
AB HIV infected patient show a profound deficit of cellular and humoral
immunity. This immunologic impairment causes a markedly increased
incidence of serious recurrent infections with opportunistic and other
microorganisms. Mostly, these infections are difficult to treat and
require hospitalization. Intravenous immunoglobulin (IVIG) has been
shown to reduce bacterial infections in HIV-infected children. In adults
a similar therapeutic approach is still a matter of debate. Therefore we
conduct a clinical trial of high dose intravenous immunoglobulin (0.4
g/kg BW initially following 2 g/kg BW every 3 weeks; Venimmun,
Behringwerke, Frankfurt, Germany) to study the effect on the frequency
of hospitalization, body weight, fever and infectious complications in
adults. Predominantly CDC IV type patients where included. In an
intermediate analysis of the trial we screened the clinical reports of
72 patients in the control group (16 ARC; 56 AIDS) and 76 patients in
the Venimmun group (14 ARC; 62 AIDS). Observation period ranges from
4-136 weeks. The two groups were comparable with regard to age and sex.
Furthermore, there was no difference concerning the transmission of HIV
in both groups. In addition we TABULAR DATA, SEE ABSTRACT VOLUME. found
a significant reduction of serious infections and in death due to
infection in the IVIG group. (8/23 control; 1/16 IVIG; death by
infection/total death). We conclude at this moment a distinct benefit of
the IVIG-therapy in HIV-infected adults.
DE Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*THERAPY Adult
AIDS-Related Complex/IMMUNOLOGY/THERAPY AIDS-Related Opportunistic
Infections/EPIDEMIOLOGY/MORTALITY/ *PREVENTION & CONTROL Body
Weight/DRUG EFFECTS Comparative Study Fever/EPIDEMIOLOGY/PREVENTION &
CONTROL Human Immunoglobulins, Intravenous/*THERAPEUTIC USE Treatment
Outcome CLINICAL TRIAL MEETING ABSTRACT RANDOMIZED CONTROLLED TRIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).